6 claims that cleared review. Each one shows what has to be true for it to hold and how strongly it is supported — including the places the sources contradict each other.
Combining a ketogenic or very-low-carbohydrate diet with an SGLT2 inhibitor substantially raises the risk of diabetic ketoacidosis, often euglycaemic, and should only be done under medical supervision or after adjusting the medication.
Ketogenic diets and SGLT2-inhibitor diabetes medicines (like empagliflozin) can combine to trigger a dangerous complication called euglycemic diabetic ketoacidosis, sometimes within days. Talk to your doctor before combining them.
Safety. Harmful if misapplied. The conditions above are not optional detail.
Only when
concurrent use of an SGLT2 inhibitor (e.g. empagliflozin, dapagliflozin) or other antidiabetic pharmacotherapy
risk applies to adults with type 2 diabetes on SGLT2 inhibitor therapy who start or are on a ketogenic/carbohydrate-restricted diet
risk is elevated further in patients with relative insulin deficiency
documented euglycaemic DKA cases occurred within the first dose or within the first week of combining the two
the American Association of Clinical Endocrinology recommends stopping SGLT2 inhibitors before starting a ketogenic diet
electrolyte-disturbance risk from the combination is mechanistically plausible but findings on that specific effect are inconsistent across studies
Who
adults with type 2 diabetes (or other conditions) taking an SGLT2 inhibitor who are considering or starting a ketogenic or very-low-carbohydrate diet
Moderate confidence
Strongest evidence tier present is observational (documented euDKA case reports), not RCT/meta-analysis, but six independent authors across six separate reviews converge without dissent, and one explicitly cites a professional-society guideline (AACE) recommending discontinuation. Narrative-review-level, not primary-trial-level, but consistent and safety-relevant.
6 independent people · 6 sources · strongest evidence: observational
Sources
Ketogenic Diet in Obesity and Diabetes: A Narrative Review. · Nutrients · 2026 · doi:10.3390/nu18122004
Ketogenic Diet: A Review of Composition Diversity, Mechanism of Action and Clinical Application. · Journal of nutrition and metabolism · 2024 · doi:10.1155/2024/6666171
Efficacy of Ketogenic Diets on Type 2 Diabetes: a Systematic Review. · Current diabetes reports · 2021 · doi:10.1007/s11892-021-01399-z
Scientific evidence underlying contraindications to the ketogenic diet: An update. · Obesity reviews : an official journal of the International Association for the Study of Obesity · 2020 · doi:10.1111/obr.13053
In adults taking semaglutide alongside metformin, mild gastrointestinal side effects -- mainly nausea, and less often diarrhea or constipation -- are common, occur mostly during treatment initiation or dose escalation, and typically improve over time without needing to discontinue either medication.
Starting semaglutide while already on metformin often causes mild nausea, and sometimes diarrhea or constipation, especially at first or when the dose goes up. This usually gets better on its own and isn't a reason to stop the medication.
Only when
most frequent at treatment initiation or during dose escalation
observed both when semaglutide is added to existing metformin and when metformin is continued after semaglutide is later withdrawn
a post hoc analysis of the SUSTAIN 6 RCT found concomitant metformin was not associated with an increased risk of serious GI adverse events, nausea, vomiting, or discontinuation compared with semaglutide alone -- i.e. adding metformin does not appear to worsen semaglutide's own GI tolerability profile
Who
adults on oral semaglutide and/or metformin, including populations with antipsychotic-induced weight gain and obese women with PCOS
Moderate confidence
Two independent observational sources (campforts-b, jensterle-m) agree, and jensterle's own cohort finding (44% GI incidence) is corroborated by a cited post hoc analysis of the SUSTAIN 6 RCT (37.6-40.3%). Both primary sources are observational rather than RCTs and jensterle's cohort is small (n=25), so confidence is moderate rather than high.
2 independent people · 2 sources · strongest evidence: observational
Sources
Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study. · BMC psychiatry · 2024 · doi:10.1186/s12888-024-06317-7
The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study. · Frontiers in Endocrinology · 2024 · doi:10.3389/fendo.2024.1366940
In people taking the carbonic-anhydrase-inhibitor anti-seizure medications topiramate or zonisamide, starting a ketogenic diet can lower serum bicarbonate and cause metabolic acidosis -- risk is highest during early diet adaptation -- and zonisamide in particular carries a theoretical added kidney-stone risk, though kidney-stone risk appears more strongly tied to diet-driven metabolic changes than to the medication itself. Discuss this with your clinician before applying it, especially if you have a diagnosed condition or take prescription medication.
If you take topiramate or zonisamide for seizures and try keto, your blood can turn too acidic, especially early on, and zonisamide may raise kidney-stone risk. Get your doctor to monitor you.
Safety. Needs medical supervision — do not act on this without a clinician.
Only when
risk of metabolic acidosis is highest during the early ketogenic-diet adaptation period
kidney-stone risk is specifically documented with zonisamide co-use (not topiramate)
kidney-stone (urolithiasis) risk appears more strongly associated with diet-driven metabolic derangements -- metabolic acidosis, concentrated urine, acidic urine, hypercalciuria, hypocitraturia -- than with medication status alone, per one cited study
one supporting source's population is specifically pediatric epilepsy patients on the ketogenic diet
Who
people on topiramate or zonisamide (carbonic-anhydrase-inhibitor anti-seizure medications) who are on or starting a ketogenic diet, including pediatric epilepsy patients
Moderate confidence
Two independent observational-tier narrative reviews (Dyńka, Newmaster) converge on the same medication-interaction warning; observational evidence is mid-tier on the ladder (below RCT and meta-analysis), and neither source is a controlled trial isolating this specific drug-diet interaction, so confidence is capped below high despite agreement.
2 independent people · 2 sources · strongest evidence: observational
A ketogenic or modified Atkins diet can lower blood levels of certain antiepileptic drugs, most consistently clobazam, so levels should be monitored after starting the diet.
Starting a ketogenic or modified Atkins diet can lower the blood level of some seizure medications, especially clobazam, so levels need to be re-checked by a doctor after beginning the diet.
Safety. Needs medical supervision — do not act on this without a clinician.
Only when
clobazam reduction is the most consistently reported effect: one study found a 42% reduction, another (a prospective study of 63 epileptic patients on modified Atkins diet) found reduced clobazam levels at 12 weeks
other antiepileptic drugs metabolised by cytochrome P450 (lamotrigine, topiramate, lacosamide, carbamazepine, valproic acid) may also fall, per one source
oxcarbazepine, zonisamide, and levetiracetam showed no change after 4-12 weeks of modified Atkins diet in the same source
one source states ketogenic diets generally do not change AED levels, with clobazam specifically named as an exception -- the two sources therefore agree on clobazam and diverge in emphasis on how broad the effect is beyond it
Who
people on antiepileptic medication, particularly clobazam, who start a ketogenic or modified Atkins diet
Moderate confidence
2 independent authors, both observational, agree specifically on the clobazam finding; the broader claim about other cytochrome-P450-metabolised AEDs comes from only one of the two sources, which is reflected in the conditions rather than asserted as consensus.
2 independent people · 2 sources · strongest evidence: observational
In adults at high risk of type 2 diabetes, metformin produces a smaller reduction in diabetes onset than intensive lifestyle change, but the modest weight loss it produces tends to be better sustained over a 10-year horizon than lifestyle-arm weight loss, which is often partly regained.
Metformin lowers diabetes risk less than diet and exercise changes do, but any weight loss from metformin tends to stick around longer -- over ten years, people on lifestyle change alone often regain some of the weight they lost.
Safety. Needs medical supervision — do not act on this without a clinician.
Only when
metformin arm reduced diabetes onset by 31%, versus a larger reduction from lifestyle intervention (see habit_formation--763f, same underlying DPP/DPPOS trial)
at 10-year follow-up (DPPOS), the metformin arm's modest weight loss was maintained while the original lifestyle-intervention arm partly regained weight over the same period
Who
adults at high risk of type 2 diabetes (prediabetes / insulin resistance)
Moderate confidence
Both members report findings from the same underlying trial (the Diabetes Prevention Program and its Outcomes Study) -- one the medication-arm effect size (RCT phase), the other the 10-year weight-durability comparison (observational follow-up phase). This is a within-trial elaboration by two independent voices reporting different endpoints of one study, not two independently replicating studies, so confidence is held at moderate rather than higher.
2 independent people · 2 sources · strongest evidence: rct
Sources
The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study. · Frontiers in Endocrinology · 2024 · doi:10.3389/fendo.2024.1366940
GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide (liraglutide, semaglutide, tirzepatide) are approved medications for type 2 diabetes and, for some agents, obesity/weight loss; they increase insulin release, inhibit glucagon secretion, and their associated weight loss may itself reduce insulin resistance.
GLP-1 medicines like semaglutide, liraglutide, and tirzepatide lower blood sugar and support weight loss, which can also improve insulin sensitivity. They're prescription medications -- talk to your doctor if you're considering one.
Safety. Needs medical supervision — do not act on this without a clinician.
Only when
liraglutide, semaglutide, and tirzepatide are the agents currently named in NICE guidance for weight loss
these agents are FDA-approved for type 2 diabetes and, for some agents, obesity
Who
adults with type 2 diabetes or obesity being considered for GLP-1 receptor agonist or GIP/GLP-1 dual agonist therapy
Moderate confidence
Strongest evidence present is clinical_experience (freeman-andrew), above the author_assertion-only cap, but this rests on only two independent narrative/review sources describing well-established drug-class pharmacology rather than a primary trial result within this cluster.
Weight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis. · Clinical obesity · 2026 · doi:10.1111/cob.70092
This is a summary of published research, not medical advice. It cannot account for your medications, conditions or history. Talk to a clinician before acting on any of it.